Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regenxbio (RGNX) Other Operating Expenses (2016 - 2025)

Regenxbio has reported Other Operating Expenses over the past 12 years, most recently at -$54000.0 for Q4 2025.

  • Quarterly results put Other Operating Expenses at -$54000.0 for Q4 2025, up 93.52% from a year ago — trailing twelve months through Dec 2025 was -$179000.0 (up 79.31% YoY), and the annual figure for FY2025 was -$179000.0, up 79.31%.
  • Other Operating Expenses for Q4 2025 was -$54000.0 at Regenxbio, up from -$65000.0 in the prior quarter.
  • Over the last five years, Other Operating Expenses for RGNX hit a ceiling of $19.2 million in Q3 2021 and a floor of -$351.3 million in Q4 2023.
  • Median Other Operating Expenses over the past 5 years was $9500.0 (2024), compared with a mean of -$12.1 million.
  • Biggest five-year swings in Other Operating Expenses: soared 20008.0% in 2021 and later tumbled 6603.44% in 2023.
  • Regenxbio's Other Operating Expenses stood at $15.0 million in 2021, then crashed by 64.09% to $5.4 million in 2022, then tumbled by 6603.44% to -$351.3 million in 2023, then skyrocketed by 99.76% to -$833000.0 in 2024, then skyrocketed by 93.52% to -$54000.0 in 2025.
  • The last three reported values for Other Operating Expenses were -$54000.0 (Q4 2025), -$65000.0 (Q3 2025), and -$45000.0 (Q2 2025) per Business Quant data.